English

Puramed Bioscience Inc.

EDGAR

Quarterly report (10-Q) · filed 2014-11-19

32 filing records in this dataset, filed from 2007-11-13 to 2014-11-19. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

3.64 thousand USD

2015 Q1 · USD

Exact inputs and evidence

Revenue: 3636 USD Source

Operating margin

-3,724.92%

2015 Q1 · %

Exact inputs and evidence

Operating Income: -135438 USD Source
Revenue: 3636 USD Source

Operating cash flow

-43.4 thousand USD

2015 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -43424 USD Source

Free cash flow

-43.4 thousand USD

2015 Q1 · USD

Exact inputs and evidence

Operating Cash Flow: -43424 USD Source
Capital Expenditure: 0 USD Source

Cash and cash equivalents: 54.7 thousand USD 2011-09-30 Source
Exact value

54664 USD
Long-term debt including current maturities: Not available
Shares outstanding: 70.7 million shares 2014-09-30 Source
Exact value

70662185 shares

Reported share-count change

17.80% · 10.7 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

59985134 shares · 2013-09-30· Source
70662185 shares · 2014-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

-5.35 million USD

2013-10-01 – 2014-09-30

Exact inputs and evidence

Net income: -910345 USD · 2013-10-01 – 2013-12-31 Source
Net income: -1944109 USD · 2014-01-01 – 2014-03-31 Source
Net income: -5225923 USD · 2013-07-01 – 2014-06-30 Source
Net income: -3557172 USD · 2013-07-01 – 2014-03-31 Source
Net income: -822649 USD · 2014-07-01 – 2014-09-30 Source

Operating cash flow

-711 thousand USD

2013-10-01 – 2014-09-30

Exact inputs and evidence

Operating cash flow: -227482 USD · 2013-07-01 – 2013-12-31 Source
Operating cash flow: -130228 USD · 2013-07-01 – 2013-09-30 Source
Operating cash flow: -389656 USD · 2013-07-01 – 2014-03-31 Source
Operating cash flow: -227482 USD · 2013-07-01 – 2013-12-31 Source
Operating cash flow: -797571 USD · 2013-07-01 – 2014-06-30 Source
Operating cash flow: -389656 USD · 2013-07-01 – 2014-03-31 Source
Operating cash flow: -43424 USD · 2014-07-01 – 2014-09-30 Source

Capital expenditure

3.66 thousand USD

2013-10-01 – 2014-09-30

Exact inputs and evidence

Capital expenditure: 232 USD · 2013-07-01 – 2013-12-31 Source
Capital expenditure: 232 USD · 2013-07-01 – 2013-09-30 Source
Capital expenditure: 232 USD · 2013-07-01 – 2014-03-31 Source
Capital expenditure: 232 USD · 2013-07-01 – 2013-12-31 Source
Capital expenditure: 3887 USD · 2013-07-01 – 2014-06-30 Source
Capital expenditure: 232 USD · 2013-07-01 – 2014-03-31 Source
Capital expenditure: 0 USD · 2014-07-01 – 2014-09-30 Source

Free cash flow

-714 thousand USD

2013-10-01 – 2014-09-30

Exact inputs and evidence

Operating cash flow: -227482 USD · 2013-07-01 – 2013-12-31 Source
Operating cash flow: -130228 USD · 2013-07-01 – 2013-09-30 Source
Operating cash flow: -389656 USD · 2013-07-01 – 2014-03-31 Source
Operating cash flow: -227482 USD · 2013-07-01 – 2013-12-31 Source
Operating cash flow: -797571 USD · 2013-07-01 – 2014-06-30 Source
Operating cash flow: -389656 USD · 2013-07-01 – 2014-03-31 Source
Operating cash flow: -43424 USD · 2014-07-01 – 2014-09-30 Source
Capital expenditure: 232 USD · 2013-07-01 – 2013-12-31 Source
Capital expenditure: 232 USD · 2013-07-01 – 2013-09-30 Source
Capital expenditure: 232 USD · 2013-07-01 – 2014-03-31 Source
Capital expenditure: 232 USD · 2013-07-01 – 2013-12-31 Source
Capital expenditure: 3887 USD · 2013-07-01 – 2014-06-30 Source
Capital expenditure: 232 USD · 2013-07-01 – 2014-03-31 Source
Capital expenditure: 0 USD · 2014-07-01 – 2014-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2014-11-19.

Financial data available through: 2014-06-30.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2014-06-30
Operating income: 6 of 11 periods available· newest 2014-06-30
Net income: 6 of 11 periods available· newest 2014-06-30
Operating cash flow: 6 of 11 periods available· newest 2014-06-30
Capital expenditure: 6 of 11 periods available· newest 2014-06-30
Total assets: 6 of 11 periods available· newest 2014-06-30
Total liabilities: 4 of 11 periods available· newest 2012-06-30
Current assets: 6 of 11 periods available· newest 2014-06-30
Current liabilities: 6 of 11 periods available· newest 2014-06-30
Cash and cash equivalents: 3 of 11 periods available· newest 2011-06-30
long term debt: No compatible figures in this window
Shares outstanding: 4 of 11 periods available· newest 2014-06-30

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
-100%

Prior period

USD 42,807

2012-07-01 – 2013-06-30
Current period

USD 0

2013-07-01 – 2014-06-30

Exact inputs and evidence

0 − 42807 = -42807 USD

42807 USD · 2012-07-01 – 2013-06-30
Inspect prior input Prior source
0 USD · 2013-07-01 – 2014-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Puramed Bioscience Inc. · 2014-06-30 Puramed Bioscience Inc. (edgar:1409565) Year-over-year change in Revenue: -42807 USD Concept: fundies:Revenue Period: 2013-07-01 to 2014-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 0 USD (2013-07-01 to 2014-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448814005105/pmbs-20140630.xml#40622 Filing: 000135448814005105 Input fundies:Revenue: 42807 USD (2012-07-01 to 2013-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448814005105/pmbs-20140630.xml#40508 Filing: 000135448814005105
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 2.66 million

Prior period

−USD 2.56 million

2012-07-01 – 2013-06-30
Current period

−USD 5.23 million

2013-07-01 – 2014-06-30

Exact inputs and evidence

-5225923 − -2562604 = -2663319 USD

-2562604 USD · 2012-07-01 – 2013-06-30
Inspect prior input Prior source
-5225923 USD · 2013-07-01 – 2014-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Puramed Bioscience Inc. · 2014-06-30 Puramed Bioscience Inc. (edgar:1409565) Year-over-year change in Net income: -2663319 USD Concept: fundies:NetIncome Period: 2013-07-01 to 2014-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -5225923 USD (2013-07-01 to 2014-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448814005105/pmbs-20140630.xml#43486 Filing: 000135448814005105 Input fundies:NetIncome: -2562604 USD (2012-07-01 to 2013-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448814005105/pmbs-20140630.xml#43359 Filing: 000135448814005105
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 528,732

Prior period

−USD 1.33 million

2012-07-01 – 2013-06-30
Current period

−USD 797,571

2013-07-01 – 2014-06-30

Exact inputs and evidence

-797571 − -1326303 = 528732 USD

-1326303 USD · 2012-07-01 – 2013-06-30
Inspect prior input Prior source
-797571 USD · 2013-07-01 – 2014-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Puramed Bioscience Inc. · 2014-06-30 Puramed Bioscience Inc. (edgar:1409565) Year-over-year change in Operating cash flow: 528732 USD Concept: fundies:OperatingCashFlow Period: 2013-07-01 to 2014-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -797571 USD (2013-07-01 to 2014-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448814005105/pmbs-20140630.xml#48173 Filing: 000135448814005105 Input fundies:OperatingCashFlow: -1326303 USD (2012-07-01 to 2013-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448814005105/pmbs-20140630.xml#47988 Filing: 000135448814005105
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+USD 3,887

Prior period

USD 0

2012-07-01 – 2013-06-30
Current period

USD 3,887

2013-07-01 – 2014-06-30

Exact inputs and evidence

3887 − 0 = 3887 USD

0 USD · 2012-07-01 – 2013-06-30
Inspect prior input Prior source
3887 USD · 2013-07-01 – 2014-06-30
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Puramed Bioscience Inc. · 2014-06-30 Puramed Bioscience Inc. (edgar:1409565) Year-over-year change in Capital expenditure: 3887 USD Concept: fundies:CapitalExpenditure Period: 2013-07-01 to 2014-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 3887 USD (2013-07-01 to 2014-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448814005105/pmbs-20140630.xml#51161 Filing: 000135448814005105 Input fundies:CapitalExpenditure: 0 USD (2012-07-01 to 2013-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448814005105/pmbs-20140630.xml#50983 Filing: 000135448814005105
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2014 2013-07-01 – 2014-06-30

Revenue USD 0
Cost of revenue USD 443,861
Operating expenses USD 2.25 million
Other operating costs Derived USD 0
Operating income −USD 2.7 million
Tax, interest and other Derived USD 2.53 million
Net income −USD 5.23 million

Cash

Operating cash flow −USD 797,571
Capital expenditure USD 3,887
Free cash flow Derived −USD 801,458

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2009 Not shown: operating income or net income is not reported.
2010 Operating loss: operating costs were 4,146% of revenue.
2011 Operating loss: operating costs were 12,751% of revenue.
2012 Operating loss: operating costs were 295% of revenue.
2013 Operating loss: operating costs were 4,785% of revenue.
2014 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2009 2008-07-01 – 2009-06-30	0	525887 Derived	-525887	-886 Derived	-525001	-196025 Derived	Source 2008-07-01 – 2009-06-30: 0 USD Inspect Revenue Open source 2008-07-01 – 2009-06-30: -525887 USD Inspect Operating Income Open source 2008-07-01 – 2009-06-30: -525001 USD Inspect Net Income Open source 2008-07-01 – 2009-06-30: -195445 USD Inspect Operating Cash Flow Open source 2008-07-01 – 2009-06-30: 580 USD Inspect Capital Expenditure Open source
2010 2009-07-01 – 2010-06-30	32176	1334005 Derived	-1301829	179127 Derived	-1480956	-942311 Derived	Source 2009-07-01 – 2010-06-30: 32176 USD Inspect Revenue Open source 2009-07-01 – 2010-06-30: -1301829 USD Inspect Operating Income Open source 2009-07-01 – 2010-06-30: -1480956 USD Inspect Net Income Open source 2009-07-01 – 2010-06-30: -940216 USD Inspect Operating Cash Flow Open source 2009-07-01 – 2010-06-30: 2095 USD Inspect Capital Expenditure Open source
2011 2010-07-01 – 2011-06-30	8593	1095687 Derived	-1087094	401839 Derived	-1488933	-613544 Derived	Source 2010-07-01 – 2011-06-30: 8593 USD Inspect Revenue Open source 2010-07-01 – 2011-06-30: -1087094 USD Inspect Operating Income Open source 2010-07-01 – 2011-06-30: -1488933 USD Inspect Net Income Open source 2010-07-01 – 2011-06-30: -606281 USD Inspect Operating Cash Flow Open source 2010-07-01 – 2011-06-30: 7263 USD Inspect Capital Expenditure Open source
2012 2011-07-01 – 2012-06-30	693060	2041735 Derived	-1348675	372694 Derived	-1721369	-705638 Derived	Source 2011-07-01 – 2012-06-30: 693060 USD Inspect Revenue Open source 2011-07-01 – 2012-06-30: -1348675 USD Inspect Operating Income Open source 2011-07-01 – 2012-06-30: -1721369 USD Inspect Net Income Open source 2011-07-01 – 2012-06-30: -704711 USD Inspect Operating Cash Flow Open source 2011-07-01 – 2012-06-30: 927 USD Inspect Capital Expenditure Open source
2013 2012-07-01 – 2013-06-30	42807	2048427 Derived	-2005620	556984 Derived	-2562604	-1326303 Derived	Source 2012-07-01 – 2013-06-30: 42807 USD Inspect Revenue Open source 2012-07-01 – 2013-06-30: -2005620 USD Inspect Operating Income Open source 2012-07-01 – 2013-06-30: -2562604 USD Inspect Net Income Open source 2012-07-01 – 2013-06-30: -1326303 USD Inspect Operating Cash Flow Open source 2012-07-01 – 2013-06-30: 0 USD Inspect Capital Expenditure Open source
2014 2013-07-01 – 2014-06-30	0	2696756 Derived	-2696756	2529167 Derived	-5225923	-801458 Derived	Source 2013-07-01 – 2014-06-30: 0 USD Inspect Revenue Open source 2013-07-01 – 2014-06-30: -2696756 USD Inspect Operating Income Open source 2013-07-01 – 2014-06-30: -5225923 USD Inspect Net Income Open source 2013-07-01 – 2014-06-30: -797571 USD Inspect Operating Cash Flow Open source 2013-07-01 – 2014-06-30: 3887 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2014

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20092009-06-30	Revenue	0	Revenue: 0 Open source
20102010-06-30	Revenue	32176	Revenue: 32176 Open source
20112011-06-30	Revenue	8593	Revenue: 8593 Open source
20122012-06-30	Revenue	693060	Revenue: 693060 Open source
20132013-06-30	Revenue	42807	Revenue: 42807 Open source
20142014-06-30	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

-100% 2014

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20092009-06-30	Year over year	No prior comparable period	Revenue: 0 Open source
20102010-06-30	Year over year	No prior comparable period	Revenue: 32176 Open source Revenue: 0 Open source
20112011-06-30	Year over year	-73.3%	Revenue: 8593 Open source Revenue: 32176 Open source
20122012-06-30	Year over year	7,965.4%	Revenue: 693060 Open source Revenue: 8593 Open source
20132013-06-30	Year over year	-93.8%	Revenue: 42807 Open source Revenue: 693060 Open source
20142014-06-30	Year over year	-100%	Revenue: 0 Open source Revenue: 42807 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -4,685.3% 2013

Net margin -5,986.4% 2013

Free cash flow margin -3,098.3% 2013

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20092009-06-30	Operating margin	Not reported	Operating Income: -525887 Open source Revenue: 0 Open source
20102010-06-30	Operating margin	-4,046%	Operating Income: -1301829 Open source Revenue: 32176 Open source
20112011-06-30	Operating margin	-12,650.9%	Operating Income: -1087094 Open source Revenue: 8593 Open source
20122012-06-30	Operating margin	-194.6%	Operating Income: -1348675 Open source Revenue: 693060 Open source
20132013-06-30	Operating margin	-4,685.3%	Operating Income: -2005620 Open source Revenue: 42807 Open source
20142014-06-30	Operating margin	Not reported	Operating Income: -2696756 Open source Revenue: 0 Open source
20092009-06-30	Net margin	Not reported	Net Income: -525001 Open source Revenue: 0 Open source
20102010-06-30	Net margin	-4,602.7%	Net Income: -1480956 Open source Revenue: 32176 Open source
20112011-06-30	Net margin	-17,327.3%	Net Income: -1488933 Open source Revenue: 8593 Open source
20122012-06-30	Net margin	-248.4%	Net Income: -1721369 Open source Revenue: 693060 Open source
20132013-06-30	Net margin	-5,986.4%	Net Income: -2562604 Open source Revenue: 42807 Open source
20142014-06-30	Net margin	Not reported	Net Income: -5225923 Open source Revenue: 0 Open source
20092009-06-30	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -195445 Open source Capital Expenditure: 580 Open source
20102010-06-30	Free cash flow margin	-2,928.6%	Revenue: 32176 Open source Operating Cash Flow: -940216 Open source Capital Expenditure: 2095 Open source
20112011-06-30	Free cash flow margin	-7,140%	Revenue: 8593 Open source Operating Cash Flow: -606281 Open source Capital Expenditure: 7263 Open source
20122012-06-30	Free cash flow margin	-101.8%	Revenue: 693060 Open source Operating Cash Flow: -704711 Open source Capital Expenditure: 927 Open source
20132013-06-30	Free cash flow margin	-3,098.3%	Revenue: 42807 Open source Operating Cash Flow: -1326303 Open source Capital Expenditure: 0 Open source
20142014-06-30	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -797571 Open source Capital Expenditure: 3887 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -797.6K 2014

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20092009-06-30	Operating cash flow	-195445	Operating Cash Flow: -195445 Open source
20102010-06-30	Operating cash flow	-940216	Operating Cash Flow: -940216 Open source
20112011-06-30	Operating cash flow	-606281	Operating Cash Flow: -606281 Open source
20122012-06-30	Operating cash flow	-704711	Operating Cash Flow: -704711 Open source
20132013-06-30	Operating cash flow	-1326303	Operating Cash Flow: -1326303 Open source
20142014-06-30	Operating cash flow	-797571	Operating Cash Flow: -797571 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -801.5K 2014

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20092009-06-30	Free cash flow	-196025	Operating Cash Flow: -195445 Open source Capital Expenditure: 580 Open source
20102010-06-30	Free cash flow	-942311	Operating Cash Flow: -940216 Open source Capital Expenditure: 2095 Open source
20112011-06-30	Free cash flow	-613544	Operating Cash Flow: -606281 Open source Capital Expenditure: 7263 Open source
20122012-06-30	Free cash flow	-705638	Operating Cash Flow: -704711 Open source Capital Expenditure: 927 Open source
20132013-06-30	Free cash flow	-1326303	Operating Cash Flow: -1326303 Open source Capital Expenditure: 0 Open source
20142014-06-30	Free cash flow	-801458	Operating Cash Flow: -797571 Open source Capital Expenditure: 3887 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

366.3% 2012

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20092009-06-30	Liabilities / assets	42.9%	Total Liabilities: 128788 Open source Total Assets: 299995 Open source
20102010-06-30	Liabilities / assets	110.4%	Total Liabilities: 305845 Open source Total Assets: 277096 Open source
20112011-06-30	Liabilities / assets	289.5%	Total Liabilities: 1168578 Open source Total Assets: 403662 Open source
20122012-06-30	Liabilities / assets	366.3%	Total Liabilities: 1466724 Open source Total Assets: 400465 Open source
2013-06-30	Liabilities / assets	Not reported	Total Assets: 476346 Open source
2014-06-30	Liabilities / assets	Not reported	Total Assets: 186338 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.01× 2014

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20092009-06-30	Current assets / current liabilities	0.35×	Current Assets: 44528 Open source Current Liabilities: 128788 Open source
20102010-06-30	Current assets / current liabilities	0.35×	Current Assets: 44785 Open source Current Liabilities: 129668 Open source
20112011-06-30	Current assets / current liabilities	0.22×	Current Assets: 192176 Open source Current Liabilities: 855735 Open source
20122012-06-30	Current assets / current liabilities	0.14×	Current Assets: 209419 Open source Current Liabilities: 1466724 Open source
20132013-06-30	Current assets / current liabilities	0.1×	Current Assets: 326244 Open source Current Liabilities: 3170999 Open source
20142014-06-30	Current assets / current liabilities	0.01×	Current Assets: 71076 Open source Current Liabilities: 5324614 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2009 2008-07-01 – 2009-06-30	−USD 525,001 Exact value Exact value: -525001 USD 2008-07-01 – 2009-06-30: -525001 USD Inspect Net Income Open source Share or cite Citation for Net Income · Puramed Bioscience Inc. · 2009-06-30 Puramed Bioscience Inc. (edgar:1409565) Net Income: -525001 USD Concept: fundies:NetIncome Period: 2008-07-01 to 2009-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565/explain?concept=fundies%3ANetIncome&period=2009-06-30&surface=latest&period_type=duration&start=2008-07-01&unit=USD&dimensions= Input fundies:NetIncome: -525001 USD (2008-07-01 to 2009-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/0001354488-11-000566.txt#4526 The citation records this snapshot. The page link may show a newer release later.	−USD 195,445 Exact value Exact value: -195445 USD 2008-07-01 – 2009-06-30: -195445 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Puramed Bioscience Inc. · 2009-06-30 Puramed Bioscience Inc. (edgar:1409565) Operating Cash Flow: -195445 USD Concept: fundies:OperatingCashFlow Period: 2008-07-01 to 2009-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565/explain?concept=fundies%3AOperatingCashFlow&period=2009-06-30&surface=latest&period_type=duration&start=2008-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -195445 USD (2008-07-01 to 2009-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/0001354488-11-000566.txt#4726 The citation records this snapshot. The page link may show a newer release later.	USD 580 Exact value Exact value: 580 USD 2008-07-01 – 2009-06-30: 580 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Puramed Bioscience Inc. · 2009-06-30 Puramed Bioscience Inc. (edgar:1409565) Capital Expenditure: 580 USD Concept: fundies:CapitalExpenditure Period: 2008-07-01 to 2009-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565/explain?concept=fundies%3ACapitalExpenditure&period=2009-06-30&surface=latest&period_type=duration&start=2008-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 580 USD (2008-07-01 to 2009-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/0001354488-11-000566.txt#4772 The citation records this snapshot. The page link may show a newer release later.	−USD 196,025 Calculation and evidence -195445 − 580 USD Exact free cash flow: -196025 USD 2008-07-01 – 2009-06-30: -195445 USD · Inspect Operating Cash Flow · Source 2008-07-01 – 2009-06-30: 580 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Puramed Bioscience Inc. · 2009-06-30 Puramed Bioscience Inc. (edgar:1409565) Free cash flow: -196025 USD Concept: free-cash-flow Period: 2008-07-01 to 2009-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -195445 USD (2008-07-01 to 2009-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/0001354488-11-000566.txt#4726 Input fundies:CapitalExpenditure: 580 USD (2008-07-01 to 2009-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/0001354488-11-000566.txt#4772 The citation records this snapshot. The page link may show a newer release later.
2010 2009-07-01 – 2010-06-30	−USD 1.48 million Exact value Exact value: -1480956 USD 2009-07-01 – 2010-06-30: -1480956 USD Inspect Net Income Open source Share or cite Citation for Net Income · Puramed Bioscience Inc. · 2010-06-30 Puramed Bioscience Inc. (edgar:1409565) Net Income: -1480956 USD Concept: fundies:NetIncome Period: 2009-07-01 to 2010-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565/explain?concept=fundies%3ANetIncome&period=2010-06-30&surface=latest&period_type=duration&start=2009-07-01&unit=USD&dimensions= Input fundies:NetIncome: -1480956 USD (2009-07-01 to 2010-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/0001354488-11-003607.txt#4703 The citation records this snapshot. The page link may show a newer release later.	−USD 940,216 Exact value Exact value: -940216 USD 2009-07-01 – 2010-06-30: -940216 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Puramed Bioscience Inc. · 2010-06-30 Puramed Bioscience Inc. (edgar:1409565) Operating Cash Flow: -940216 USD Concept: fundies:OperatingCashFlow Period: 2009-07-01 to 2010-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565/explain?concept=fundies%3AOperatingCashFlow&period=2010-06-30&surface=latest&period_type=duration&start=2009-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -940216 USD (2009-07-01 to 2010-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/0001354488-11-003607.txt#4903 The citation records this snapshot. The page link may show a newer release later.	USD 2,095 Exact value Exact value: 2095 USD 2009-07-01 – 2010-06-30: 2095 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Puramed Bioscience Inc. · 2010-06-30 Puramed Bioscience Inc. (edgar:1409565) Capital Expenditure: 2095 USD Concept: fundies:CapitalExpenditure Period: 2009-07-01 to 2010-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565/explain?concept=fundies%3ACapitalExpenditure&period=2010-06-30&surface=latest&period_type=duration&start=2009-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2095 USD (2009-07-01 to 2010-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/0001354488-11-003607.txt#4949 The citation records this snapshot. The page link may show a newer release later.	−USD 942,311 Calculation and evidence -940216 − 2095 USD Exact free cash flow: -942311 USD 2009-07-01 – 2010-06-30: -940216 USD · Inspect Operating Cash Flow · Source 2009-07-01 – 2010-06-30: 2095 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Puramed Bioscience Inc. · 2010-06-30 Puramed Bioscience Inc. (edgar:1409565) Free cash flow: -942311 USD Concept: free-cash-flow Period: 2009-07-01 to 2010-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -940216 USD (2009-07-01 to 2010-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/0001354488-11-003607.txt#4903 Input fundies:CapitalExpenditure: 2095 USD (2009-07-01 to 2010-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/0001354488-11-003607.txt#4949 The citation records this snapshot. The page link may show a newer release later.
2011 2010-07-01 – 2011-06-30	−USD 1.49 million Exact value Exact value: -1488933 USD 2010-07-01 – 2011-06-30: -1488933 USD Inspect Net Income Open source Share or cite Citation for Net Income · Puramed Bioscience Inc. · 2011-06-30 Puramed Bioscience Inc. (edgar:1409565) Net Income: -1488933 USD Concept: fundies:NetIncome Period: 2010-07-01 to 2011-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565/explain?concept=fundies%3ANetIncome&period=2011-06-30&surface=latest&period_type=duration&start=2010-07-01&unit=USD&dimensions= Input fundies:NetIncome: -1488933 USD (2010-07-01 to 2011-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448812005262/pmbs-20120630.xml#121415 Filing: 000135448812005262 The citation records this snapshot. The page link may show a newer release later.	−USD 606,281 Exact value Exact value: -606281 USD 2010-07-01 – 2011-06-30: -606281 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Puramed Bioscience Inc. · 2011-06-30 Puramed Bioscience Inc. (edgar:1409565) Operating Cash Flow: -606281 USD Concept: fundies:OperatingCashFlow Period: 2010-07-01 to 2011-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565/explain?concept=fundies%3AOperatingCashFlow&period=2011-06-30&surface=latest&period_type=duration&start=2010-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -606281 USD (2010-07-01 to 2011-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448812005262/pmbs-20120630.xml#146828 Filing: 000135448812005262 The citation records this snapshot. The page link may show a newer release later.	USD 7,263 Exact value Exact value: 7263 USD 2010-07-01 – 2011-06-30: 7263 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Puramed Bioscience Inc. · 2011-06-30 Puramed Bioscience Inc. (edgar:1409565) Capital Expenditure: 7263 USD Concept: fundies:CapitalExpenditure Period: 2010-07-01 to 2011-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565/explain?concept=fundies%3ACapitalExpenditure&period=2011-06-30&surface=latest&period_type=duration&start=2010-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7263 USD (2010-07-01 to 2011-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448812005262/pmbs-20120630.xml#172270 Filing: 000135448812005262 The citation records this snapshot. The page link may show a newer release later.	−USD 613,544 Calculation and evidence -606281 − 7263 USD Exact free cash flow: -613544 USD 2010-07-01 – 2011-06-30: -606281 USD · Inspect Operating Cash Flow · Source 2010-07-01 – 2011-06-30: 7263 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Puramed Bioscience Inc. · 2011-06-30 Puramed Bioscience Inc. (edgar:1409565) Free cash flow: -613544 USD Concept: free-cash-flow Period: 2010-07-01 to 2011-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -606281 USD (2010-07-01 to 2011-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448812005262/pmbs-20120630.xml#146828 Filing: 000135448812005262 Input fundies:CapitalExpenditure: 7263 USD (2010-07-01 to 2011-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448812005262/pmbs-20120630.xml#172270 Filing: 000135448812005262 The citation records this snapshot. The page link may show a newer release later.
2012 2011-07-01 – 2012-06-30	−USD 1.72 million Exact value Exact value: -1721369 USD 2011-07-01 – 2012-06-30: -1721369 USD Inspect Net Income Open source Share or cite Citation for Net Income · Puramed Bioscience Inc. · 2012-06-30 Puramed Bioscience Inc. (edgar:1409565) Net Income: -1721369 USD Concept: fundies:NetIncome Period: 2011-07-01 to 2012-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565/explain?concept=fundies%3ANetIncome&period=2012-06-30&surface=latest&period_type=duration&start=2011-07-01&unit=USD&dimensions= Input fundies:NetIncome: -1721369 USD (2011-07-01 to 2012-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448813005721/pmbs-20130630.xml#67566 Filing: 000135448813005721 The citation records this snapshot. The page link may show a newer release later.	−USD 704,711 Exact value Exact value: -704711 USD 2011-07-01 – 2012-06-30: -704711 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Puramed Bioscience Inc. · 2012-06-30 Puramed Bioscience Inc. (edgar:1409565) Operating Cash Flow: -704711 USD Concept: fundies:OperatingCashFlow Period: 2011-07-01 to 2012-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565/explain?concept=fundies%3AOperatingCashFlow&period=2012-06-30&surface=latest&period_type=duration&start=2011-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -704711 USD (2011-07-01 to 2012-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448813005721/pmbs-20130630.xml#52263 Filing: 000135448813005721 The citation records this snapshot. The page link may show a newer release later.	USD 927 Exact value Exact value: 927 USD 2011-07-01 – 2012-06-30: 927 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Puramed Bioscience Inc. · 2012-06-30 Puramed Bioscience Inc. (edgar:1409565) Capital Expenditure: 927 USD Concept: fundies:CapitalExpenditure Period: 2011-07-01 to 2012-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565/explain?concept=fundies%3ACapitalExpenditure&period=2012-06-30&surface=latest&period_type=duration&start=2011-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 927 USD (2011-07-01 to 2012-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448813005721/pmbs-20130630.xml#52967 Filing: 000135448813005721 The citation records this snapshot. The page link may show a newer release later.	−USD 705,638 Calculation and evidence -704711 − 927 USD Exact free cash flow: -705638 USD 2011-07-01 – 2012-06-30: -704711 USD · Inspect Operating Cash Flow · Source 2011-07-01 – 2012-06-30: 927 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Puramed Bioscience Inc. · 2012-06-30 Puramed Bioscience Inc. (edgar:1409565) Free cash flow: -705638 USD Concept: free-cash-flow Period: 2011-07-01 to 2012-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -704711 USD (2011-07-01 to 2012-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448813005721/pmbs-20130630.xml#52263 Filing: 000135448813005721 Input fundies:CapitalExpenditure: 927 USD (2011-07-01 to 2012-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448813005721/pmbs-20130630.xml#52967 Filing: 000135448813005721 The citation records this snapshot. The page link may show a newer release later.
2013 2012-07-01 – 2013-06-30	−USD 2.56 million Exact value Exact value: -2562604 USD 2012-07-01 – 2013-06-30: -2562604 USD Inspect Net Income Open source Share or cite Citation for Net Income · Puramed Bioscience Inc. · 2013-06-30 Puramed Bioscience Inc. (edgar:1409565) Net Income: -2562604 USD Concept: fundies:NetIncome Period: 2012-07-01 to 2013-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565/explain?concept=fundies%3ANetIncome&period=2013-06-30&surface=latest&period_type=duration&start=2012-07-01&unit=USD&dimensions= Input fundies:NetIncome: -2562604 USD (2012-07-01 to 2013-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448814005105/pmbs-20140630.xml#43359 Filing: 000135448814005105 The citation records this snapshot. The page link may show a newer release later.	−USD 1.33 million Exact value Exact value: -1326303 USD 2012-07-01 – 2013-06-30: -1326303 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Puramed Bioscience Inc. · 2013-06-30 Puramed Bioscience Inc. (edgar:1409565) Operating Cash Flow: -1326303 USD Concept: fundies:OperatingCashFlow Period: 2012-07-01 to 2013-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565/explain?concept=fundies%3AOperatingCashFlow&period=2013-06-30&surface=latest&period_type=duration&start=2012-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1326303 USD (2012-07-01 to 2013-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448814005105/pmbs-20140630.xml#47988 Filing: 000135448814005105 The citation records this snapshot. The page link may show a newer release later.	USD 0 Exact value Exact value: 0 USD 2012-07-01 – 2013-06-30: 0 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Puramed Bioscience Inc. · 2013-06-30 Puramed Bioscience Inc. (edgar:1409565) Capital Expenditure: 0 USD Concept: fundies:CapitalExpenditure Period: 2012-07-01 to 2013-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565/explain?concept=fundies%3ACapitalExpenditure&period=2013-06-30&surface=latest&period_type=duration&start=2012-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 0 USD (2012-07-01 to 2013-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448814005105/pmbs-20140630.xml#50983 Filing: 000135448814005105 The citation records this snapshot. The page link may show a newer release later.	−USD 1.33 million Calculation and evidence -1326303 − 0 USD Exact free cash flow: -1326303 USD 2012-07-01 – 2013-06-30: -1326303 USD · Inspect Operating Cash Flow · Source 2012-07-01 – 2013-06-30: 0 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Puramed Bioscience Inc. · 2013-06-30 Puramed Bioscience Inc. (edgar:1409565) Free cash flow: -1326303 USD Concept: free-cash-flow Period: 2012-07-01 to 2013-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1326303 USD (2012-07-01 to 2013-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448814005105/pmbs-20140630.xml#47988 Filing: 000135448814005105 Input fundies:CapitalExpenditure: 0 USD (2012-07-01 to 2013-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448814005105/pmbs-20140630.xml#50983 Filing: 000135448814005105 The citation records this snapshot. The page link may show a newer release later.
2014 2013-07-01 – 2014-06-30	−USD 5.23 million Exact value Exact value: -5225923 USD 2013-07-01 – 2014-06-30: -5225923 USD Inspect Net Income Open source Share or cite Citation for Net Income · Puramed Bioscience Inc. · 2014-06-30 Puramed Bioscience Inc. (edgar:1409565) Net Income: -5225923 USD Concept: fundies:NetIncome Period: 2013-07-01 to 2014-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565/explain?concept=fundies%3ANetIncome&period=2014-06-30&surface=latest&period_type=duration&start=2013-07-01&unit=USD&dimensions= Input fundies:NetIncome: -5225923 USD (2013-07-01 to 2014-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448814005105/pmbs-20140630.xml#43486 Filing: 000135448814005105 The citation records this snapshot. The page link may show a newer release later.	−USD 797,571 Exact value Exact value: -797571 USD 2013-07-01 – 2014-06-30: -797571 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Puramed Bioscience Inc. · 2014-06-30 Puramed Bioscience Inc. (edgar:1409565) Operating Cash Flow: -797571 USD Concept: fundies:OperatingCashFlow Period: 2013-07-01 to 2014-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565/explain?concept=fundies%3AOperatingCashFlow&period=2014-06-30&surface=latest&period_type=duration&start=2013-07-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -797571 USD (2013-07-01 to 2014-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448814005105/pmbs-20140630.xml#48173 Filing: 000135448814005105 The citation records this snapshot. The page link may show a newer release later.	USD 3,887 Exact value Exact value: 3887 USD 2013-07-01 – 2014-06-30: 3887 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Puramed Bioscience Inc. · 2014-06-30 Puramed Bioscience Inc. (edgar:1409565) Capital Expenditure: 3887 USD Concept: fundies:CapitalExpenditure Period: 2013-07-01 to 2014-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565/explain?concept=fundies%3ACapitalExpenditure&period=2014-06-30&surface=latest&period_type=duration&start=2013-07-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 3887 USD (2013-07-01 to 2014-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448814005105/pmbs-20140630.xml#51161 Filing: 000135448814005105 The citation records this snapshot. The page link may show a newer release later.	−USD 801,458 Calculation and evidence -797571 − 3887 USD Exact free cash flow: -801458 USD 2013-07-01 – 2014-06-30: -797571 USD · Inspect Operating Cash Flow · Source 2013-07-01 – 2014-06-30: 3887 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Puramed Bioscience Inc. · 2014-06-30 Puramed Bioscience Inc. (edgar:1409565) Free cash flow: -801458 USD Concept: free-cash-flow Period: 2013-07-01 to 2014-06-30 Values: Latest reported Published: 2026-11-02T17:06:37Z Snapshot: 3a509375cb8e3c03185536788b87a162eec4edd930b1f49822e23b1ef2d17fd7 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1409565?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -797571 USD (2013-07-01 to 2014-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448814005105/pmbs-20140630.xml#48173 Filing: 000135448814005105 Input fundies:CapitalExpenditure: 3887 USD (2013-07-01 to 2014-06-30) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1409565/000135448814005105/pmbs-20140630.xml#51161 Filing: 000135448814005105 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

32 filings · 879 latest values · 879 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001409565, 1409565, edgar:1409565

Also known as Puramed Bioscience Inc.

Puramed Bioscience Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2014 2013-07-01 – 2014-06-30

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation